Results 91 to 100 of about 4,937 (255)

Pleomorphic xanthoastrocytoma with anaplastic features: one case report and review of literature

Chinese Journal of Contemporary Neurology and Neurosurgery, 2014
Objective To investigate the clinicopathological features of pleomorphic xanthoastrocytoma with anaplastic features (PXA-A).  Methods The clinical manifestations, imaging, histopathological features, and immunophenotype were analyzed in one case of ...
Cui-yun SUN, Shi-zhu YU
doaj  

Genotype‐directed therapy for non–small cell lung cancer diagnosed during pregnancy: A pooled analysis of seven cases from the Cancer and Pregnancy Registry with maternal and neonatal outcomes and review of the literature

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
In this retrospective case series from a single database of pregnant women with cancer, seven were diagnosed with non‐small cell lung cancer (NSCLC). Chemotherapy and in some cases also biomarker‐directed therapy during pregnancy were associated with disease control allowing delivery closer to term and resulting in improved maternal outcomes compared ...
Reed Firestone, Elyce Cardonick
wiley   +1 more source

Anaplastic pleomorphic xanthoastrocytoma

Chinese Journal of Contemporary Neurology and Neurosurgery, 2017
Objective To investigate the clinicopathological features, immune phenotype and gene mutation characteristics, and diagnosis or differential diagnosis of anaplastic pleomorphic xanthoastrocytoma (PXA).
Li-wei SHAO, Fu-lin WANG
doaj  

AOSNP‐ADAPTR resource level‐based recommendations on practical diagnostic strategies for ependymomas

Brain Pathology, EarlyView.
Adapting Diagnostic Approaches for Practical Taxonomy in Resource‐Restrained Regions (ADAPTR) recommendations for ependymomas in resource‐restrained settings (RL = resource level; created in BioRender). Abstract Ependymomas are uncommon primary tumors of the central nervous system (CNS) that affect both children and adults.
Laveniya Satgunaseelan, Michael E. Buckland, Geeta Chacko, Kenta Masui, Junji Shibahara, Vani Santosh, Maysa Al‐Hussaini, Sung‐Hye Park, Tarik Tihan, Ho‐Keung Ng, Pieter Wesseling, David N. Louis, Chitra Sarkar, Takashi Komori   +13 more
wiley   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Clinical and Imaging Features of Tepotinib‐Induced Interstitial Lung Disease in the Post‐Marketing Setting in Japan

Cancer Science, EarlyView.
This article reports on the clinical and imaging features of tepotinib‐induced interstitial lung disease (ILD), which were evaluated by an ILD adjudication committee composed of external respiratory and radiology experts, and the committee expertly identified 35 patients with tepotinib‐induced ILD from spontaneous adverse event reports accumulated in ...
Terufumi Kato, Tomohisa Baba, Masahiro Endo, Shehla Endo, Eisuke Horii, Masahiko Kusumoto   +5 more
wiley   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

Five‐Year Trends in Biomarker Testing and Targeted Therapy for NSCLC: A Patient‐Initiated Nationwide Survey in Japan

Cancer Science, EarlyView.
This nationwide survey reveals that comprehensive multigene testing for advanced NSCLC has rapidly expanded in Japan, steadily increasing the use of targeted therapies for rare oncogenic drivers. Despite these diagnostic advancements, approximately 30% of patients consistently remain untested, highlighting a persistent clinical gap in real‐world ...
Satoshi Ikeda, Kazuo Hasegawa, Takayuki Takahama, Kenta Kachi, Akihiro Yanagisawa, Sachiko Kawakami, Masashi Yoshida, Miyuki Sakai, Sachiko Watanabe, Kazuhiko Nakagawa   +9 more
wiley   +1 more source

The different face of skin‐rash induced by brentuximab vedotin

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri, Tullio Brunetti, Serena Rupoli, Gianluca Cafasso, Corrado Zengarini, Staphano Cedirian, Federico Bardazzi, Cosimo Misciali, Michela Starace, Claudio Agostinelli, Gaia Goteri, Erika Morsia   +11 more
wiley   +1 more source